Lonza Group

Lonza Group is the world's largest contract development and manufacturing organisation (CDMO) for biologics, serving Big Pharma and biotech clients with everything from clinical-trial supply to commercial-scale production of monoclonal antibodies, gene therapies, and increasingly GLP-1 peptide drugs (Wegovy, Mounjaro, Zepbound). The 2024-2025 narrative was a turbulent transition: Lonza divested its lower-margin Capsules & Health Ingredients division in early 2025, simultaneously absorbing the $1.2 billion Vacaville (California) biologics facility purchased from Genentech — the largest single-site mammalian-cell production facility in the world. The 2026 story is the integration win. Vacaville comes online with multi-year client commitments already booked, GLP-1 capacity sells out roughly 18 months ahead of demand, and gene-therapy CDMO services remain the highest-margin sub-segment with limited credible competition. CEO Wolfgang Wienand has guided FY2026 organic revenue growth of 12-15%, with core EBITDA margin recovering to 30%+ as Vacaville absorption costs run off. The strategic narrative has flipped from «execution turnaround» to «growth compounder with manufacturing scarcity premium».

The smart-money base in Lonza is a mix of Swiss long-only legacy (UBS, Pictet, Bellevue), specialist pharma/healthcare funds (BB Biotech, RTW Investments), and global high-quality compounders (Fundsmith, Lindsell Train). Terry Smith's Fundsmith has been a top-15 holder since 2022 and added through the 2024 selloff — an unusually high-conviction signal given his concentration. There has been no major activist pressure, partly because the Swiss-board governance structure makes activism mechanically harder, but also because the Vacaville-plus-GLP-1 thesis has been broadly accepted by the long-only universe. On the short side, hedge funds focused on biologic-manufacturing oversupply risk have been bearish — Samsung Biologics, WuXi Biologics, and incumbent in-house capacity at Roche/Genentech all could in theory soften pricing. So far this thesis has not played out.

Lonza trades at 19.5× forward earnings and 13× EV/EBITDA — both meaningful premiums to general industrials but discounts to peers Catalent (pre-acquisition 22×) and Samsung Biologics (28×). The valuation embeds successful Vacaville integration and continued GLP-1 capacity scarcity. The FCF yield is roughly 2.5% — modest now, but expected to expand to 5%+ by 2028 as capex normalises. Bull case (Vacaville ramps smoothly, GLP-1 contracts extended, gene-therapy margins hold): CHF 720. Base case (steady execution, no major surprises): CHF 595. Bear case (Vacaville delay + GLP-1 in-sourcing + competitive capacity additions): CHF 420.

1. July 24, 2026: H1/2026 results — first half with material Vacaville contribution; watch for capacity utilization metrics.
2. October 2026: Q3/2026 trading update — visibility into GLP-1 contract renewals for 2027-2028.
3. February 2027: FY2026 full results + 2027-2030 mid-term guidance refresh — expected confirmation of 30%+ EBITDA margin trajectory.

Lonza is one of my higher-conviction European holdings (3% portfolio weight). The thesis is simple: biologic manufacturing capacity is structurally scarce, gene therapy is just beginning its commercial decade, and GLP-1 demand is going to compound for at least another 3-5 years. Owning the most credible neutral manufacturing partner with the largest installed capacity is the asset-light way to play biotech innovation without picking individual drug winners. Where I'd be cautious for a new entry: the multi-year ramp risk on Vacaville is real, and CHF 600-plus is not a cheap absolute valuation. Wait for a 10-15% pullback before adding, or scale in over six months. But the 2026-2028 growth trajectory is among the most visible in European large-caps.